According to Gram Research analysis, anamorelin, a drug that helps cancer patients regain appetite and weight, lasted longer in people treated at an earlier stage of cachexia. Those early-stage patients stayed on treatment a median of 211.5 days, versus 34.5 days for patients at a later stage. Starting sooner, while patients are still in better physical shape, may matter most.

Cancer cachexia is a condition where people lose muscle and body weight, often making it harder to keep up with cancer treatment. According to research reviewed by Gram, a medicine called anamorelin may work better when started earlier. Researchers at two Japanese hospitals reviewed the records of 98 patients who received anamorelin between 2021 and 2025. Patients caught at an earlier stage of the condition kept taking the medicine for a median of 211.5 days, compared with 34.5 days for those at a later stage. Patients who were still physically active at the start also stayed on treatment longer, with a median of 71 days compared with 25 days for those who were less active. The study also found that new diagnostic guidelines for Asian patients did not change how doctors prescribed the drug. The findings suggest that earlier treatment may be important, though this was a records review and not a controlled trial.

Key Statistics

A 2026 retrospective chart review of 98 patients at two Japanese hospitals found that people at an earlier stage of cancer cachexia stayed on anamorelin for a median of 211.5 days, compared with 34.5 days for those with full cachexia.

In the same 2026 study, patients with a baseline performance status of 0 to 1 continued anamorelin for a median of 71 days, compared with 25 days for patients with a status of 2 to 4 (p below 0.001).

The 2026 study reported that the prescribing pattern of anamorelin did not substantially change after the 2023 Asian Working Group for Cachexia criteria were introduced, with 68 patients in the earlier period and 30 in the later period.

The Quick Take

  • What they studied: The researchers wanted to know whether doctors had started prescribing anamorelin differently after new diagnostic guidelines for Asian patients were introduced in 2023. They also wanted to know whether the stage of the condition and a patient’s physical condition at the start affected how long people stayed on the medicine.
  • Who participated: The study included 98 adults with cancer cachexia who were prescribed anamorelin at two hospitals in Yokohama, Japan, between April 2021 and March 2025. Out of 130 people prescribed the drug, 98 had records complete enough to be included. Most patients (90) had full cachexia, and only 8 had an earlier, pre-cachexia stage.
  • Key finding: Patients at the earlier stage stayed on anamorelin for a median of 211.5 days, while patients at the full cachexia stage stayed on it for a median of 34.5 days. This difference was statistically significant, meaning it was unlikely to be due to chance alone. Patients who were more physically active at the start also stayed on treatment longer, with a median of 71 days compared with 25 days.
  • What it means for you: The results suggest that starting treatment earlier, while a person is still in relatively good shape, may help the medicine work for a longer period. Because the study looked at medical records rather than comparing treatments directly, it cannot prove that earlier treatment causes better results. Anyone dealing with weight loss during cancer treatment should talk with their oncology team about their options.

The Research Details

This was a retrospective chart review, which means the researchers looked back at existing medical records instead of enrolling new patients and assigning them to treatments. They reviewed the records of patients who received anamorelin at Showa Medical University Hospital and Showa Medical University Northern Yokohama Hospital between April 2021 and March 2025.

The main measure was how long each patient continued taking the medicine. The researchers also tracked changes in each patient’s performance status, a standard score that describes how well a person can handle daily activities. Patients were grouped by whether they were prescribed before or after the 2023 Asian Working Group for Cachexia guidelines were introduced, and by their stage of cachexia and their starting performance status.

To compare how long people stayed on the drug, the team used a statistical method that tracks when each patient stopped treatment. This approach is common in cancer research because it accounts for patients who were still taking the medicine when the study ended.

Looking at real medical records shows how a treatment is actually used in everyday clinical practice, not just in ideal trial conditions. This helps answer practical questions, such as whether new guidelines have changed how doctors prescribe the drug. Tracking how long patients stay on a treatment also gives a useful sense of whether it is helping them in real life.

The approach has limits, however. Doctors chose who received the drug and when, so patients who started earlier may have differed in other ways from those who started later. A randomized trial would be needed to show cause and effect more clearly.

The study comes from a single group of hospitals, so its results may not apply to all patients or all health systems. The sample is also uneven: 90 patients had full cachexia, while only 8 had the earlier pre-cachexia stage. Results based on such a small group are less reliable and can shift with only a few patients.

The analysis used standard statistical tests, and the key comparisons were reported with p-values, a common measure of how likely a result is to be due to chance. Still, because this was a review of past records, some information may have been missing or recorded inconsistently. The study was published in a peer-reviewed journal, which means outside experts reviewed it before publication.

What the Results Show

Anamorelin is a medicine designed to help people with cancer cachexia regain appetite and body weight. Of the 98 patients analyzed, 68 were prescribed the drug before the new Asian guidelines were introduced and 30 were prescribed it afterward. The researchers found no major differences in patient characteristics between the two groups, and the way doctors prescribed the drug did not clearly change after the guidelines came out.

The most striking result involved the stage of the condition. Patients at the earlier pre-cachexia stage stayed on anamorelin for a median of 211.5 days, while those with full cachexia stayed on it for a median of 34.5 days. The difference was statistically significant, with a p-value of 0.013. Because only 8 patients had pre-cachexia, this finding should be treated as a starting point rather than a firm answer.

Physical condition at the start of treatment also mattered. Patients with a performance status of 0 to 1, meaning they were still fairly active and able to care for themselves, stayed on the drug for a median of 71 days. Patients with a status of 2 to 4, meaning they were more limited, stayed on it for a median of 25 days. This difference was highly significant, with a p-value below 0.001. The researchers also found that patients’ performance status did not decline markedly over time while on the drug.

The researchers reported that performance status generally stayed stable during treatment, which suggests that the drug did not cause a clear drop in patients’ daily functioning. This is reassuring, but the study did not directly measure muscle mass or weight changes in a way that would confirm the drug’s benefit.

The team also looked at whether the new Asian diagnostic criteria changed practice. The answer was largely no. This suggests that updated guidelines alone may not change treatment decisions unless doctors and health systems actively put them into use.

Cancer cachexia has long been diagnosed using criteria developed mainly in Western populations. Researchers have increasingly worried that these criteria may miss early cases in Asian patients. The 2023 Asian Working Group guidelines were proposed to address this gap, and this study checks whether they have affected real prescribing. Earlier research on anamorelin has generally focused on whether the drug improves weight and appetite in clinical trials, so this study adds useful information about timing in everyday practice.

The finding that earlier treatment is linked to longer use fits with the broader idea that cancer-related weight loss is easier to address before it becomes severe. Still, this is an observational review, so it adds context rather than settling the question.

This was a review of medical records from only two hospitals, so the results may not reflect patients elsewhere. Doctors decided who got the drug and when, which can create differences between patient groups that have nothing to do with the medicine itself. For example, patients who were healthier may have been more likely to be started early and to stay on treatment.

The study included only 8 patients with the earlier pre-cachexia stage, which makes that finding less certain. The team also did not measure directly how much weight or muscle patients gained, and they did not report whether the drug helped patients live longer or handle cancer treatment better. Finally, the 32 patients excluded from the original 130 may differ from those included, which could affect the results.

The Bottom Line

Research reviewed by Gram suggests that anamorelin may be more useful when started at an earlier stage of cachexia and when a patient is still relatively active. Confidence in this idea is moderate, because it comes from a single observational study with a small number of early-stage patients. Confidence is higher that updated diagnostic guidelines alone did not change prescribing in this group. Patients and families should discuss the timing of treatment with their care team rather than waiting for symptoms to become severe.

This research is most relevant to people with cancer who are experiencing unplanned weight loss, muscle loss, or appetite problems, and to their families and caregivers. Oncologists, palliative care teams, and dietitians may also find it useful when deciding when to begin supportive treatment. People without cancer, or those whose weight changes have other causes, should not apply these findings directly without medical advice.

In this study, patients who started earlier stayed on anamorelin for a median of about seven months, while those with more advanced disease stayed on it for about one month. Individual experiences will vary widely, and any changes in appetite or weight should be tracked with a doctor over several weeks to months. Benefits, if any, are best judged over a period of at least a few months.

Frequently Asked Questions

How long do cancer patients typically stay on anamorelin for cachexia?

In a 2026 review of 98 patients at two Japanese hospitals, the median time on anamorelin was 211.5 days for those at an earlier cachexia stage and 34.5 days for those with full cachexia. Duration varied widely between individuals, so results will differ for each person.

Does starting anamorelin earlier help cancer weight loss?

A 2026 observational study suggests earlier treatment may be linked to longer use of anamorelin, but it cannot prove that starting earlier causes better results. Patients who were more active at the start also stayed on treatment longer, so timing and general condition may both matter.

What is cancer cachexia and how is it diagnosed in Asian patients?

Cancer cachexia is a condition involving significant weight loss, muscle loss, and reduced appetite in people with cancer. In 2023, the Asian Working Group for Cachexia proposed diagnostic criteria designed to identify cases earlier in Asian populations than older Western-based criteria did.

Did new cachexia guidelines change how doctors prescribe anamorelin?

A 2026 study of anamorelin prescriptions at two Japanese hospitals found no substantial change after the 2023 Asian diagnostic criteria were introduced. Of the 98 patients analyzed, 68 were prescribed the drug before the new criteria and 30 after.

Want to Apply This Research?

  • Record your body weight at the same time of day, about three times per week, along with a simple daily appetite score from 1 (very poor) to 5 (normal or better). Also note your daily energy level and how many days per week you can complete your usual activities. Share these trends with your care team at each visit.
  • Use the app to log meals and snacks, aiming for small, frequent portions if appetite is low. Set reminders for regular protein-containing foods and fluids, and check in with your dietitian about adding calorie-dense options. Keep a short note of activities you can still manage each week, since staying active may support better treatment outcomes.
  • Review weight, appetite, and activity trends every two to four weeks and bring the summaries to your oncology appointments. Watch for sustained weight loss, a drop in daily functioning, or new symptoms, and report them promptly. Over time, the data can help your care team decide whether to continue, adjust, or change treatment.

This article summarizes a retrospective review of medical records and is for general education only. It is not medical advice and does not replace guidance from your oncology team, dietitian, or other healthcare provider. Anamorelin is a prescription medicine, and decisions about starting, continuing, or stopping it should be made with a qualified clinician who knows your full medical history.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Trends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation. , Annals of nutrition & metabolism (2026). PubMed 43058071 | DOI
Topics
anamorelin cancer cachexia cancer weight loss appetite stimulant Asian diagnostic criteria performance status cancer nutrition treatment timing